Show an ad over header. AMP

I am the second

Biogen says FDA didn't push for trial before Alzheimer's approval

Two Biogen executives said in an interview the company's newly approved Alzheimer's drug is priced fairly, and that it didn't conduct another clinical trial before approval because the FDA didn't push them to do so.

Why it matters: The scientific consensus is the drug, Aduhelm, has not been proven to work. But Biogen and the FDA are content with "hopefully" validating the $56,000 drug's efficacy at some unknown point in the future.

Keep reading... Show less

Related Articles

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories